Beijing Hope Pharmaceutical Co., Ltd. is a high-tech pharmaceutical company based in China and facing the world. The main business is R&D, production and sales of APIs and APIs, import and export trade, R&D of new pharmaceutical preparations and new drug registration. We have an R&D center in Beijing, a pharmaceutical intermediate production base in Hebei and Zhejiang, and a GMP-certified API production base in Shandong.
*The following content is generated by AI and is for reference only.
Tianeptine, often mistakenly referred to as "tianeptine acid," is a tricyclic antidepressant with a unique pharmacological profile that distinguishes it from conventional agents. Its systematic chemical name is 3-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)imino]-1,3-diazepane-2-sulfonic acid sodium salt. The molecular formula for the active free acid form is C19H22N2O4S, while the commercially available sodium salt formulation is C19H21N2NaO4S. The CAS number for tianeptine itself is 38716-17-5, whereas its sodium salt carries the CAS identifier 49836-89-7.
Originally synthesized in France during the late 1970s, tianeptine functions primarily by modulating glutamatergic transmission and enhancing serotonin reuptake, though its exact mechanism involves complex interactions with opioid receptors and neuroplasticity pathways. Unlike many standard antidepressants, it does not significantly affect heart rate or blood pressure, making it a favorable option for patients with cardiovascular concerns. Clinically, it is widely prescribed for the treatment of major depressive disorder and anxiety-related conditions across Europe, Asia, and parts of South America. It has also shown promise in managing irritable bowel syndrome due to its anxiolytic effects on the gut-brain axis.
Despite its therapeutic efficacy, tianeptine faces significant regulatory scrutiny in certain regions, particularly the United States, where it is not approved by the FDA for medical use. In recent years, non-medical use has emerged as a concern due to reports of misuse associated with opioid-like effects when taken in high doses. This has led to controlled substance scheduling in various jurisdictions to prevent abuse. Legitimate pharmaceutical applications remain focused on depression and anxiety management under strict medical supervision. The drug is typically administered orally in tablet or liquid forms, with dosages carefully titrated based on individual patient response. Ongoing research continues to explore its potential in treating stress-induced cognitive decline and other neuropsychiatric disorders, highlighting its unique position within the psychopharmacology landscape.